WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H522701
CAS#: 774549-97-2
Description: KM11060 is a mutated F508del cystic fibrosis transmembrane conductance regulator (CFTR) corrector. The most common mutation (~90%) in the CFTR gene is a deletion of phenylalanine 508 (F508del). KM11060 is an analog of sildenafil, which restores a function of the F508del mutated CFTR chloride channel. KM11060 appears to be more potent than sildenafil, forskolin, and genistein.
Hodoodo Cat#: H522701
Name: KM11060
CAS#: 774549-97-2
Chemical Formula: C19H17Cl2N3O2S
Exact Mass: 421.04
Molecular Weight: 422.324
Elemental Analysis: C, 54.04; H, 4.06; Cl, 16.79; N, 9.95; O, 7.58; S, 7.59
Synonym: KM11060; KM-11060; KM 11060.
IUPAC/Chemical Name: 7-chloro-4-(4-((4-chlorophenyl)sulfonyl)piperazin-1-yl)quinoline
InChi Key: GIEHIZKCIZLXLF-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H17Cl2N3O2S/c20-14-1-4-16(5-2-14)27(25,26)24-11-9-23(10-12-24)19-7-8-22-18-13-15(21)3-6-17(18)19/h1-8,13H,9-12H2
SMILES Code: O=S(N1CCN(C2=CC=NC3=CC(Cl)=CC=C23)CC1)(C4=CC=C(Cl)C=C4)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 422.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Wu H, Yang J, Su EM, Li L, Zhao C, Yang X, Gao Z, Pan M, Sun P, Sun W, Jiang
Y, Su X. Lipoxin A4 and platelet activating factor are involved in E. coli or
LPS-induced lung inflammation in CFTR-deficient mice. PLoS One. 2014 Mar
26;9(3):e93003. doi: 10.1371/journal.pone.0093003. eCollection 2014. PubMed PMID:
24671173; PubMed Central PMCID: PMC3966846.
2: Loo TW, Bartlett MC, Shi L, Clarke DM. Corrector-mediated rescue of
misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump. Biochem
Pharmacol. 2012 Feb 1;83(3):345-54. doi: 10.1016/j.bcp.2011.11.014. Epub 2011 Nov
28. PubMed PMID: 22138447.
3: Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, Luo Y, Zhang D, Thomas
DY, Hanrahan JW. Structural analog of sildenafil identified as a novel corrector
of the F508del-CFTR trafficking defect. Mol Pharmacol. 2008 Feb;73(2):478-89.
Epub 2007 Nov 1. PubMed PMID: 17975008.
